Phase 2 Breast Cancer Trial, Recruiting NCT07276880 Sponsor: UNC Lineberger Comprehensive Cancer Center Condition: Breast Cancer
Back to Breast Cancer

Phase 2 Breast Cancer Trial, Recruiting

NCT07276880
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are willing and able to sign a consent form agreeing to take part in the study and allowing their personal health information to be used.
  • People who are able to follow the study procedures, as determined by the study doctor.
  • People who are 18 years of age or older at the time of signing the consent form.
  • People who have a good general level of physical functioning, as measured by standard medical scoring tools (confirm with trial site for exact score requirements).

Who may not be able to join:

  • People who currently have an active infection that requires treatment with medications taken by mouth or through a drip.
  • People who are pregnant or currently breastfeeding.
  • People who have previously had radiation therapy to the same side of the breast, chest wall, or chest area.
  • People who have previously had invasive breast cancer on the same side, invasive breast cancer on the opposite side, or another type of invasive cancer that is still progressing or required active treatment within the last 5 years.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Dana Casey, MD, UNC Lineberger Comprehensive Cancer Center

Phone: 919-984-0000

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
UNC Lineberger Comprehensive Cancer Center
Registry
ClinicalTrials.gov
Start date
17 March 2026
Est. completion
1 November 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Nodal Pathologic Complete Response rate(pCR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov